Magnesium supplementation to prevent high blood pressure in pregnancy: a randomised placebo control trial
- 863 Downloads
To assess if hypertension during the last part of pregnancy could be prevented by magnesium supplementation.
Pregnant primagravida women from a local antenatal care unit were given an oral supply of 300 mg magnesium as citrate or placebo from pregnancy week 25 in a randomised double-blind setup. Blood pressure was recorded during pregnancy as well as pregnancy outcome.
In the magnesium-supplemented group, the average diastolic blood pressure at week 37 was significantly lower than in the placebo group (72/1.4 mean/SEM vs 77/1.4, p = 0.031). The number of women with an increase in diastolic blood pressure of ≥15 mmHg was significantly lower in the magnesium group compared with the women who received placebo (p = 0.011). There was an inverse relation between the urinary excretion of magnesium during pregnancy and the diastolic blood pressure (p = 0.005).
Magnesium supplementation prevented an increase in diastolic blood pressure during the last weeks of pregnancy. The relation between diastolic blood pressure and urinary excretion of magnesium suggests that magnesium is involved in the regulation of blood pressure and that the increase in diastolic blood pressure in pregnancy could be due to a lack of magnesium.
KeywordsPregnancy-induced hypertension Magnesium Prevention
The study was supported by grants from the Research and Development Foundation at Södra Älvsborg, Alice Swenzon’s Foundation, Swedbank Sjuhärad Research Foundation, Sweden, and Protina GmbH, Ismaning, Germany.
Ethical committee approval was obtained (ECG T 515-10, 098-09, Ethical Committee, Gothenburg University 8 April 2009) as well as permission to register according to Swedish law on personal information. Informed consent was obtained from all participants. Registration at ISRCTN98365455.
Conflict of interest
The authors report no conflict of interest. Dr Vormann is a scientific consultant to Protina GmbH.
- 1.(2000) Report of the national high blood pressure program working group on high blood pressure in pregnancy. Am J Obstet Gynecol 183:S1–S22Google Scholar
- 4.Richie LD, King JC (2001) Dietary calcium and pregnancy-induced hypertension: is there a relation? Am J Clin Nutr 71(suppl):1371S–1374SGoogle Scholar
- 12.Indumati V, Kodliwadmath MV, Sheela MK (2011) The role of serum electrolytes in pregnancy induced hypertension. J Clin Diagnostic Res 5:66–69Google Scholar
- 18.Duley L, Matar HE, Almerie MQ, Hal lDR (2010) Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia. Cochrane Database Syst Rev 8:CD0077388:1Google Scholar
- 20.Sugimoto J, Romani AM, Valentin-Torres AM, Luciano AA, Ramirez-Kitchen CM, Funderburg N, Mesiano S et al (2012) Magnesium decreases inflammatory cytokine production: a novel innate immunomodulatory mechanism. J Immunol 188:6338–6346Google Scholar
- 21.Amash A, Weintraub AY, Sheiner E, Zeadna A, Huleihel M, Holcberg G (2010) Possible therapeutic effect of magnesium sulphate in pre-eclampsia by the down-regulation of placental tumor necrosis factor-alpha secretion. Eur Cytokine Netw 1:58–64Google Scholar
- 26.Makrides M, Crowther CA (2001) Magnesium supplementation in pregnancy. Cochrane Database Syst Rev (4):CD000937. doi: 10.1002/14651858.CD000937
- 28.Rylander R, Tallheden T, Vormann J (2009) Acid–base conditions regulate calcium and magnesium homeostasis. Magnesium Res 22:1–4Google Scholar
- 29.Rylander R, Remer T, Berkemeyer S, Vormann J (2006) Acid–base status affects renal magnesium losses in healthy, elderly persons. J Nutrition 36:2374–2377Google Scholar